Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | ACACA | Q13085 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23269622 | 0.98 | CYP1A2 (0.59) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL8136294 | 0.92 | CYP1A2 (0.61) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL15508283 | 0.87 | CYP1A2 (0.52) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL27717811 | 0.86 | L3MBTL3 (0.57) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL21610969 | 0.85 | CYP1A2 (0.53) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL1464487 | 0.84 | L3MBTL3 (0.55) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL4550241 | 0.83 | POLB (0.50) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL13088446 | 0.83 | POLB (0.55) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL4706209 | 0.82 | ACACB (0.44) | CYP1A2TDP1L3MBTL3L3MBTL1ACACB | |
| SCHEMBL1732383 | 0.82 | L3MBTL3 (0.54) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661422-A | Synthesis method of 1- (1-methylpiperidine-4-yl) piperazine tri-hydrochloride | 白银京宇新药业有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-2066659-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | claimed |
| CN-119661422-A | Synthesis method of 1- (1-methylpiperidine-4-yl) piperazine tri-hydrochloride | 白银京宇新药业有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023083330-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 百极优棠(广东)医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2022078470-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022012623-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021104441-A1 | POLYAROMATIC COMPOUND AS EGFR KINASE INHIBITOR | 江苏先声药业有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2017076355-A1 | PYRIMIDINE DERIVATIVE AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CYP1A2 3732/4885TDP1 2009/4885L3MBTL3 4709/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CYP1A2 3953/4885TDP1 2392/4885L3MBTL3 4049/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CYP1A2 4160/4885TDP1 2783/4885L3MBTL3 4164/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | CYP1A2 2440/4885TDP1 4045/4885L3MBTL3 4642/4885 |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CYP1A2 1145/4885TDP1 1569/4885L3MBTL3 4615/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CYP1A2 3732/4885TDP1 2009/4885L3MBTL3 4709/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CYP1A2 3732/4885TDP1 2009/4885L3MBTL3 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.